Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.

Schnitzler's syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety of human monoclonal anti-human IL-1 antibody (canakinumab) use in SchS therapy.